

E3330, APE1 inhibitor/ferroptosis inducer

Catalog	Unit
TBI4000-5MG	5 mg
TBI4000-25MG	25 mg

Product Details

Formal Name: (2E)-2-[(4,5-Dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylidene]undecanoic acid

Alternate Names: (2E)-3-[5-(2,3-Dimethoxy-6-methyl-1,4-benzoquinoyl)]-2-nonyl-2-propenoic acid

Molecular Formula: C₂₁H₃₀O₆

Formula Weight: 378.5

CAS Number: 136164-66-4


Purity: >98%

Formulation: Powder

Solubility: Soluble in DMSO (>25 mg/mL)

Storage: -20°C

Stability: ≥ 2 years.



Applications

APE1 inhibitor/ferroptosis inducer

Functions

Hepatoprotective benzoquinone that inhibits TNF- α release via decreasing NF κ B activation. It also is an inhibitor of AP endonuclease 1 (APE1) redox function. E3330 acts synergistically with cisplatin to increase cytotoxicity and impair cell migration and invasion in non-small cell lung cancer. Inhibition of APE1 with E3330 induces ferroptosis via impairment of AKT phosphorylation ultimately leading to Nrf2 degradation. It sensitizes osteosarcoma cells to ionizing radiation via ferroptosis induction.

Application Procedures

First dissolved in DMSO (>25 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.

For research use only.